Sinclair Research poaches Covance, Lilly veteran Wakefield

(Image: AstraZeneca)

Preclinical contract research organization Sinclair Research has carved out a new role for G. Alex Wakefield as he becomes its vice president of research and operations.

Here, the former Covance and Eli Lilly executive will have overall responsibility for the company’s research services and its operational processes, while also being charged with “driving the growth of Sinclair’s business model and fostering positive relationships with new and current customers,” according a company statement.

Sinclair offers animal efficacy models, IND-enabling toxicology services and research capabilities to biopharma, animal health and medical device companies.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Alex’s combination of experience across pharma and CRO services coupled with his scientific knowledge of both efficacy and safety animal modeling will enable Sinclair to move to the next level in size, scope and market leadership,” said Guy Bouchard, Sinclair president.

“2017 was an outstanding year for Sinclair Research, particularly related to GLP services and regulatory compliance. As a seasoned industry executive, Alex’s proven leadership skills will be invaluable as we continue to grow our business.”

Suggested Articles

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.